Tolero Pharmaceuticals

68 articles about Tolero Pharmaceuticals

• Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical

  7/1/2020

  Sumitomo Dainippon Pharma Oncology Is Positioned to Advance Meaningful Therapies for Patients with Cancer through Innovative Drug Discovery, Research and Development

• Tolero Pharmaceuticals Presents Biomarker Identification Strategies for Investigational Agents Alvocidib and TP-1287 at AACR Virtual Meeting II 2020

  6/22/2020

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematologic and oncologic diseases, today presented findings

• Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia at Virtual EHA Annual Congress 2020

  6/12/2020

   Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the completed Phase 1 Zella 101 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in adult patients with newly diagnosed acute myeloid

• Tolero Pharmaceuticals Presents Findings from First Clinical Studies Evaluating Investigational Agents TP-1287 and TP-3654 in Patients with Advanced Solid Tumors at ASCO Virtual Annual Meeting 2020

  5/29/2020

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies evaluating the oral investigational agents TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, and TP-3654, a PIM kinase inhibitor, in p

• Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator TP-1454

  5/19/2020

   Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its investigational small-molecule pyruvate kinase M2 isoform

• Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)

  5/14/2020

  First Patient Dosed with Optimized One-Hour Dosing Schedule for Investigational Agent Alvocidib After Azacitidine

• Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia

  3/26/2020

   Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that it has joined The Leukemia & Lymphoma Society (LLS) in the groundbreaking, collaborative Beat AML Master Clinical Trial for newly diagnosed patients 60 years of ag

• Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy

  1/15/2020

  Tolero Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in patients with acute myeloid leukemia who have either relapsed from or are refractory to venetoclax in combination with a hypomethylating agent.

• Tolero Pharmaceuticals Presents Findings from Preclinical Studies Evaluating Investigational Agents TP-1287 in Prostate Cancer Models and TP-1454 in Colorectal Cancer Models

  10/29/2019

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, announced today the presentation of preclinical data of TP-1287, an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor, in castration-sensitive and resistant prostate cancer models and TP-1454, an investigational small-molecule pyruvate kinase M2 isoform (PKM2) activator, in colorectal cancer models

• Tolero Pharmaceuticals Presents Preliminary Findings from Phase 1 Study Evaluating Investigational Agent TP-0903 in Patients with Advanced Solid Tumors at ESMO 2019

  9/28/2019

  Tolero Pharmaceuticals, Inc. presented new data from the ongoing Phase 1 study evaluating the maximum tolerated dose of the oral investigational agent TP-0903, an AXL receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

• Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019

  6/14/2019

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data for the first time from the ongoing Phase 1 Zella 101 study evaluating the safety and clinical activity of alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia (AML).

• Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase 1/2 Study in Patients with Previously Treated Chronic Lymphocytic Leukemia andSmall Lymphocytic Lymphoma

  6/12/2019

  Tolero Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0903, an AXL receptor tyrosine kinase inhibitor, in patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

• Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors

  5/30/2019

  The maximum tolerated dose (MTD) of TP-0903 was established during the Phase 1a portion of the study, allowing the study to advance to the Phase 1b stage.

• Tolero Pharmaceuticals to Highlight Clinical Data Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed AML at EHA 2019

  5/16/2019

  Tolero Pharmaceuticals, Inc. announced that new data from two abstracts on the Company's investigational pipeline will be presented at the 24th Congress of the European Hematology Association, taking place June 13-16, 2019 in Amsterdam, The Netherlands.

• Tolero Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of Investigational Agent TP-3654 in Patients with Advanced Solid Tumors

  5/14/2019

  Tolero Pharmaceuticals, Inc. announced the first patient has been dosed in a Phase 1 study evaluating the investigational agent TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors.

• Tolero Pharmaceuticals to Present New Data Evaluating Investigational Agents TP-0903 and TP-0184 at AACR Annual Meeting 2019

  2/27/2019

  Tolero Pharmaceuticals, Inc. announced that new data from five abstracts on the company's pipeline of investigational agents will be presented at the American Association for Cancer Research Annual Meeting, taking place March 29-April 3, 2019 in Atlanta, Georgia.

• Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors

  1/10/2019

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been dosed in a Phase 1 study evaluating the investigational agent TP-1287,

• Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018

  12/1/2018

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented new data from the ongoing Phase 2 Zella 201 study evaluating the efficacy and safety of the investigational agent alvocidib, a potent CDK9 inhibitor, in combination with cytarabine and mitoxantrone in patients with MCL-1-dependent relapsed or refractory (R/R) acute myeloid leukemia (AML)

• Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors

  11/15/2018

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the presentation of clinical and preclinical data supporting the development of TP-0903 for the treatment of patients with solid tumors.

• Tolero Pharmaceuticals to Highlight New Data Evaluating Investigational Agents Alvocidib and TP-1287 at 2018 American Society of Hematology Annual Meeting

  11/2/2018

  Tolero Pharmaceuticals, Inc. today announced that new data from three abstracts on the Company's pipeline of investigational agents will be presented at the 60th Annual Meeting of the American Society of Hematology (ASH), December 1-4 in San Diego, California.